Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476410 · ClinicalTrials.gov registry record · Phase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT01476410 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 49 participants.
The verdict
NCT01476410, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This phase II trial studies how well giving brentuximab vedotin together with combination chemotherapy works in treating older patients with previously untreated stage II-IV Hodgkin lymphoma (HL). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, and dacarbazine (AVD), work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving brentuximab vedotin, doxorubicin hydrochloride, vinblastine, and dacarbazine together may kill more cancer cells.
Interventions
- PROCEDURE quality-of-life assessment
- DRUG brentuximab vedotin
- DRUG vinblastine
- DRUG dacarbazine
- DRUG doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2011-11 |
| Est. Completion | 2020-05-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01476410
The ClinicalTrials.gov registry entry for NCT01476410 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which quality-of-life assessment is the first listed.
NCT01476410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01476410 about?
NCT01476410 is a clinical study titled "Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma". This phase II trial studies how well giving brentuximab vedotin together with combination chemotherapy works in treating older patients with previously untreated stage II-IV Hodgkin lymphoma (HL). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ...
What is the current status of trial NCT01476410?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2011-11. Estimated completion is 2020-05-26.
What interventions are being tested in trial NCT01476410?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), brentuximab vedotin (DRUG), vinblastine (DRUG), dacarbazine (DRUG), doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01476410?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.